Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evolus Inc (EOLS)
NASDAQ:EOLS
Holding EOLS?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$0.02Last Year’s EPS
-$0.12Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2024
|% Change Since: -35.22%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, successful product expansion, and positive long-term financial projections. However, it also addressed challenges such as operating losses, cash burn, and market softness in the filler category. The company's strategic initiatives and product launches are expected to drive future growth.Company Guidance
During the third quarter of 2024, Evolus reported significant financial growth, with a 22% increase in net revenue, reaching $61 million, compared to the previous year. The company also maintained a strong customer reorder rate of over 70% and added more than 600 purchasing accounts. Evolus' adjusted gross margin stood at 70.2%, and the team emphasized their goal to achieve profitability in the fourth quarter of 2024 and for the full year 2025. Looking ahead, Evolus aims to reach at least $700 million in net revenues by 2028, driven by a compounded annual growth rate of 28% since 2023. The company also plans to expand operating margins to at least 20% by 2028. In terms of product developments, Evolus highlighted the approval of Estyme in Europe and anticipated the launch of Evolysse in the U.S. by September 2025, showcasing their strategy to leverage their digital platform and cash-pay model to strengthen consumer engagement and brand loyalty.Record Revenue Growth
Evolus reported a 33% year-to-date revenue increase compared to 2023, with third-quarter net revenue reaching $61 million, a 22% growth over the prior year.
Successful Product Expansion
Approval of Estyme in Europe marks Evolus as one of only 5 companies globally with a portfolio of injectable aesthetic products, enhancing its product offerings.
Strong Customer Retention
Evolus added over 600 purchasing accounts in Q3 with a reorder rate over 70% and achieved over 1 million consumers enrolled in the Evolus Rewards program.
Launch of Club Evolus
Evolus launched the first subscription-based consumer membership program which doubled treatment frequency compared to the industry average in its pilot.
Positive Financial Projections
Evolus is targeting $700 million in net revenues by 2028, with a 28% CAGR and 20% operating margin, supported by strategic investments and financial management.
---
EOLS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EOLS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $16.81 | $14.29 | -14.99% |
| Jul 31, 2024 | $12.42 | $14.04 | +13.04% |
| May 07, 2024 | $13.42 | $13.26 | -1.19% |
| Mar 07, 2024 | $14.79 | $14.07 | -4.87% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Evolus Inc (EOLS) report earnings?
Evolus Inc (EOLS) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Evolus Inc (EOLS) earnings time?
Evolus Inc (EOLS) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EOLS EPS forecast?
EOLS EPS forecast for the fiscal quarter 2024 (Q4) is $0.02.
---